MedTrace Logo

Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma

NCT00116363 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2008-04-01

No results posted yet for this study

Summary

This is a research study to look at the ways in which a treatment called INGN241 can kill melanoma cells or help the patient's immune system kill melanoma cells.

Conditions

  • Malignant Melanoma
  • Neoplasm Metastasis

Interventions

GENETIC

investigational drug INGN 241

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    collaborator OTHER

  • Introgen Therapeutics

    lead INDUSTRY

Principal Investigators

  • Kevin B Kim, MD · UT MD Anderson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Completion
2006-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00116363 on ClinicalTrials.gov